Hemostasia y trombosis

HEMOSTASIA Y TROMBOSIS

Este grupo se dedica desde su inicio al estudio del factor von Willebrand y su proteasa ADAMTS13 desde sus implicancias fisiológicas hasta su patología. Identificación de mutaciones para el diagnóstico de patologías relacionadas con sus alteraciones. Inhibición o estimulación del sistema VWF/ADAMTS13 por diferentes factores fisiopatológicos. Mecanismos de acción. Modelos in vitro e in vivo.

Directora: Dra. Analía Sánchez Luceros
Investigador Adjunto – CONICET

Descargar CV

Investigadores

Líneas de investigación

Publicaciones

Type 2N von Willebrand disease: Is it always a recessive trait? Woods AI, Rossetti LC, Paiva J, De Brasi CD, Romero ML, Casinelli MM, Blanco AN, Sánchez-Luceros A. Thromb Res. 2021;198:49-51. doi: 10.1016/j.thromres.2020.11.029. Epub 2020 Nov 28. PMID: 33285477.
Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina. Dos Santos C, Paiva J, Romero ML, et al. eJHaem. 2021; 2: 149–156. https://doi.org/10.1002/jha2.154
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial. Iseas S, Roca EL, O’Connor JM, Eleta M, Sanchez-Luceros A, et al. Invest New Drugs. 2020;38(5):1580-1587. doi: 10.1007/s10637-020-00914-5. Epub 2020 Mar 12. PMID: 32166534; PMCID: PMC7497699.
Biomarcadores y blancos moleculares del complemento en el diagnóstico de las microangiopatías trombóticas. Mogollón N, Rotondo S, Dos Santos C, Sánchez-Luceros A. Acta bioquím. clín. latinoam. 2020; 54(4): 437-453.
Combined effects of two mutations in von Willebrand disease 2M phenotype. Woods AI, Paiva J, Kempfer AC, Primrose DM, Blanco AN, Sanchez-Luceros A, Lazzari MA. Res Pract Thromb Haemost. 2017 Dec 20;2(1):162-167. doi: 10.1002/rth2.12067. eCollection 2018 Jan.PMID:30046717
Prevalence of Fabry Disease in Young Patients with Stroke in Argentina. Reisin RC, Mazziotti J, Cejas LL, Zinnerman A, Bonardo P, Pardal MF, Martínez A, Riccio P, Ameriso S, Bendersky E, Nofal P, Cairola P, Jure L, Sotelo A, Rozenfeld P, Ceci R, Casas-Parera I, Sánchez-Luceros A; AISYF Investigators. J Stroke Cerebrovasc Dis. 2018 Mar;27(3):575-582. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.045. Epub 2017 Nov 11. PMID:29132836
Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp). Bermejo E, Alberto MF, Paul DS, Cook AA, Nurden P, Sanchez Luceros A, Nurden AT, Bergmeier W. Platelets. 2018 Jan;29(1):84-86. doi: 10.1080/09537104.2017.1332759. Epub 2017 Jul 20. PMID:28726538
Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation. Woods AI, Kempfer AC, Paiva J, Sanchez-Luceros A, Bermejo E, Chuit R, Alberto MF, Blanco AN, Lazzari MA. Semin Thromb Hemost. 2017 Feb;43(1):92-100. doi: 10.1055/s-0036-1597293. Epub 2016 Dec 15. PMID:27978591
PT-VWD posing diagnostic and therapeutic challenges – small case series. Sánchez-Luceros A, Woods AI, Bermejo E, Shukla S, Acharya S, Lavin M, Rydz N, Othman M. Platelets. 2017 Jul;28(5):484-490. doi: 10.1080/09537104.2016.1237625. Epub 2016 Nov 7. PMID:27819553
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, Guthmann MD, Di Leo D, Spitzer E, Ciccia GN, Garona J, Pifano M, Torbidoni AV, Gomez DE, Ripoll GV, Gomez RE, Demarco IA, Alonso DF. Springerplus. 2015 Aug 19;4:428. doi: 10.1186/s40064-015-1217-y. eCollection 2015. PMID:26306290
Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease. Woods AI, Sanchez-Luceros A, Bermejo E, Paiva J, Alberto MF, Grosso SH, Kempfer AC, Lazzari MA. Semin Thromb Hemost. 2014 Mar;40(2):151-60. doi: 10.1055/s-0033-1364183. Epub 2014 Jan 28. PMID:24474090
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, Guthmann MD, Di Leo D, Spitzer E, Ciccia GN, Garona J, Pifano M, Torbidoni AV, Gomez DE, Ripoll GV, Gomez RE, Demarco IA, Alonso DF. Springerplus. 2015 Aug 19;4:428. doi: 10.1186/s40064-015-1217-y. eCollection 2015. PMID: 26306290
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. Dos Santos C, Tijeras-Raballand A, Serova M, Sebbagh S, Slimane K, Faivre S, de Gramont A, Raymond E.Br J Cancer. 2015 Jan 6;112(1):86-94. doi: 10.1038/bjc.2014.578. Epub 2014 Nov 25. PMID:25422908
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A. Oncotarget. 2015 Aug 28;6(25):21614-27. PMID: 26057634
Relationship between endothelial progenitor cells and vascular endothelial growth factor and its variation with exercise. Gagliardi JA, Maciel N, Castellano JL, Masoli O, Miksztowicz V, Berg G, Bermejo E, Lazzari M, Gelpi RJ. Thromb Res. 2016 Jan;137:92-6. doi: 10.1016/j.thromres.2015.11.012. Epub 2015 Nov 7. PMID: 26577258
PT-VWD posing diagnostic and therapeutic challenges – small case series. Sanchez-Luceros A, Woods AI, Bermejo E, Shukla S, Acharya S, Lavin M, Rydz N, Othman M.Sánchez-Luceros A, Woods AI, Bermejo E, Shukla S, Acharya S, Lavin M, Rydz N, Othman M.Platelets. 2017 Jul;28(5):484-490. doi: 10.1080/09537104.2016.1237625. Epub 2016 Nov 7. PMID: 27819553
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A. Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542. PMID: 27509260
Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation. Woods AI, Kempfer AC, Paiva J, Sanchez-Luceros A, Bermejo E, Chuit R, Alberto MF, Blanco AN, Lazzari MA. SeminThrombHemost. 2017 Feb;43(1):92-100. doi: 10.1055/s-0036-1597293. Epub 2016 Dec 15. PMID: 27978591
Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp). Bermejo E, Alberto MF, Paul DS, Cook AA, Nurden P, Sanchez Luceros A, Nurden AT, Bergmeier W. Platelets.2017 Jul 20:1-3.doi: 10.1080/09537104.2017.1332759. [Epub ahead of print] PMID: 28726538
Studies of the antitumor mechanism of action of dermaseptin B2, a multifunctional cationic antimicrobial peptide, reveal a partial implication of cell surface glycosaminoglycans. Dos Santos C, Hamadat S, Le Saux K, Newton C, Mazouni M, Zargarian L, Miro-Padovani M, Zadigue P, Delbé J, Hamma-Kourbali Y, Amiche M. PLoS One. 2017 Aug 10;12(8):e0182926. doi: 10.1371/journal.pone.0182926. eCollection 2017. PMID: 28797092
Assessmentof the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Tajer C et al. ClinApplThrombHemost. (2017)